Comparison of effectiveness and safety for low versus full dose of apixaban during extended phase oral anticoagulation in patients with venous thromboembolism.

Christina E DeRemerEric A DietrichHye-Rim KangPei-Lin HuangWei-Hsuan Lo-CiganicHaesuk Park

Published in: Journal of internal medicine (2022)

This study provides evidence that apixaban 2.5 mg twice daily is an alternative option for extended phase therapy for risk reduction of VTE recurrence compared to apixaban 5 mg twice daily.

Keyphrases

venous thromboembolism
direct oral anticoagulants
physical activity
atrial fibrillation
free survival